What the research shows
In a phase 1 pilot involving three men, two showed increased pigmentation on follow-up. The researchers assessed color visually and by measuring reflected light. Volunteers also reported nausea. With three participants and brief follow-up, the study could detect an immediate signal but could not estimate long-term risks. Read the first human pilot.
FDA describes concerns about peptide impurities and aggregation and summarizes published case reports of serious events. Case reports can flag a problem without establishing its frequency. Read FDA’s Melanotan II entry.
Documented formats
The phase 1 report gives the full structure of its cyclic peptide and describes the saline comparator. Matching the name alone leaves the structure unverified.
Testing and purity
Look for the specified ring closure, modified amino acids and terminal groups on a lot’s identity report. An amino acid list alone omits the ring.
How to read a batch reportQuestions about Melanotan II
How did the team measure pigmentation?
Alongside visual assessment, the researchers measured reflected light at several areas of skin, including the face and upper body.
What separates MT-II from afamelanotide?
MT-II has a shorter, cyclic structure. A clinical finding for an afamelanotide implant belongs to that separate molecule and product.